Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia.

Autor: Gil KB; University of Colorado School of Medicine, Denver, CO, USA., Abbott D; Center for Innovative Design and Analysis, Department of Biostatistics and Informatics, University of Colorado, Denver, CO, USA., Amaya ML; University of Colorado School of Medicine, Denver, CO, USA., Schwartz M; University of Colorado School of Medicine, Denver, CO, USA., Gutman JA; University of Colorado School of Medicine, Denver, CO, USA., Kent A; University of Colorado School of Medicine, Denver, CO, USA., Bosma G; Center for Innovative Design and Analysis, Department of Biostatistics and Informatics, University of Colorado, Denver, CO, USA., Pollyea DA; University of Colorado School of Medicine, Denver, CO, USA., McMahon CM; University of Colorado School of Medicine, Denver, CO, USA.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2024 Sep 04, pp. 1-3. Date of Electronic Publication: 2024 Sep 04.
DOI: 10.1080/10428194.2024.2397570
Databáze: MEDLINE